Cardiovascular Disease & Mortality in Diabetes Stephen Fava MD, MRCP(UK), FEFIM, FACP, FRCP (Lond), MPhil (Malta), PhD (Exeter) Consultant Physician, Diabetologist.

Slides:



Advertisements
Similar presentations
Lysaght, J Am Soc Nephrol, 2002 Number of patients worldwide treated with chronic dialysis from 1990 to ,000 1,490,000 2,500,000.
Advertisements

University of Minnesota – School of Nursing Spring Research Day Glycemic Control of Critically Ill Patients Lynn Jensen, RN; Jessica Swearingen, BCPS,
Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
Trial profile Fox K et al. Lancet 2008;372:
The concept of Diabetes & CV risk: A lifetime risk challenge Diabetes & CV Risk: Routine practice versus guidelines Eberhard Standl, MD Professor of Medicine.
Hemoglobin A 1c in Hemodialysis Patients Source: Ix JH. Hemoglobin A1c in hemodialysis patients: Should one size fit all? Clin J Am Soc Nephrol. 2010;5:1539–1541.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
RENAL DISEASE IN DIABETES
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Randomized, double-blind, multicenter, controlled trial.
Glycemic Control for myocardial infraction. Why??????
Complete Recovery of Renal Function After Acute Kidney Injury is Associated with Long-Term All-Cause Mortality In a Large Managed Care Organization Jennifer.
Modern Management of Cholesterol in the High-Risk Patient.
FDA Endocrinologic and Metabolic Drugs Advisory Committee 1st June 2008 Rury Holman Clinical outcomes with anti-diabetic drugs: What we already know.
Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Consider testing if person is: – Overweight or obese with additional risk factor for diabetes – Age 45 or older Obtain: A1C or FPG or 2-hour plasma glucose.
Hyperglycemia and Acute Coronary Syndromes. Cardiovascular disease and diabetes Bell DSH. Diabetes Care. 2003;26: Centers for Disease Control.
Glycemic Control: When the Lower is Not the “Better”?
Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyorala K for the 4S Group Reduced Coronary Events in Simvastatin-Treated.
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
1 Part 1 Importance of Identifying and Managing Postprandial Hyperglycemia An Educational Service from G LYCO M ARK G LYCO M ARK is a registered trademark.
Achieving Glycemic Control in the Hospital Setting Part 1 of 3
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Impact of Diabetes on Cardiovascular Risk C.Richard Conti M.D. MACC Oct 16,2004 GWICC Beijing, PRC.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Therapy of Type 2 Diabetes Mellitus: UPDATE Glycemic Goals in the Care of Patients with Type 2 Diabetes ADA and AACE Guidelines: Room For Improvement.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
4S: Scandinavian Simvastatin Survival Study
Preoperative Hemoglobin A1c and the Occurrence of Atrial Fibrillation Following On-pump Coronary Artery Bypass surgery in Type-2 Diabetic Patients Akbar.
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.
Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence, Temporal Trends, and Prognostic Impact.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship Between Operator Volume and Adverse.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Prognostic Value of N-Terminal Pro–B-Type Natriuretic.
Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Prognosis of Acute Kidney Injury After.
DIABETES AS A RISK FACTOR FOR COGNITIVE DECLINE IN OLDER PATIENTS F. Limongi, A. Marseglia, S. Maggi, M. Noale, G. Romanato, P. Siviero, G. Crepaldi CNR,
Clinical Outcomes with Newer Antihyperglycemic Agents
Clinical Outcomes with Newer Antihyperglycemic Agents
Alcohol, Other Drugs, and Health: Current Evidence July–August 2017
The SPRINT Research Group
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
Table 1. Baseline Characteristics of the 36,636 Study Subjects
Clinical need for determination of vulnerable plaques
Copyright © 2006 American Medical Association. All rights reserved.
Copyright © 2009 American Medical Association. All rights reserved.
Systolic Blood Pressure Intervention Trial (SPRINT)
The percentage of subjects with de novo development of renal function impairment (GFR
The following slides highlight a report on a presentation at the Late-breaking Trials Session and a Satellite Symposium of the American Heart Association.
Baseline characteristics of patients
Baseline characteristics of HPS participants by prior diabetes
Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care  Marc Cohen, MD  Mayo Clinic Proceedings 
Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Flow chart of search strategy
Michael R. Lattanzio, Matthew R. Weir  Kidney International 
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Hazard ratios, with 95% confidence intervals as floating absolute risks, as estimate of association between category of updated mean haemoglobin A1c concentration.
Presentation transcript:

Cardiovascular Disease & Mortality in Diabetes Stephen Fava MD, MRCP(UK), FEFIM, FACP, FRCP (Lond), MPhil (Malta), PhD (Exeter) Consultant Physician, Diabetologist & Endocrinologist Head of Diabetes & Endocrine Centre, Mater Dei Hospital, Malta Mater Dei Hospital, Malta

Huxley, R. et al. BMJ 2006;332:73-78 Overall summary estimates of relative risks and 95% confidence intervals for fatal coronary heart disease in men and women with and without diabetes in 22 studies that reported both age and multiple adjusted coefficients

Glycaemia and Mortality Kaplan-Meier survival curves according to quartiles of HBA1c log rank test P < Menon V et al. Glycosylated hemoglobin and mortality in patients with nondiabetic chronic kidney disease. J Am Soc Nephrol Nov;16(11):3411-7

Isolated post-challenge hyperglycaemia and mortality Cumulative survival (males) Time (days) Normal Isolated fasting hyperglycaemia Combined fasting / postprandial hyperglycaemia Isolated postprandial hyperglycaemia Known DM Shaw JE et al. Diabetologia 1999;42:1050 Pooled data from 3 population-based longitudinal studies (in Mauritius, Fiji and Nauru)

196 T2 diabetic subjects and 196 age- & sex- matched non-diabetic controls with AMI were recruited Patients with IGT were excluded Biochemical & clinical parameters were measured at baseline & during hospital stay Outcome Of AMI in Diabetes (Fava S et al, Diabetes Care 16:1615-8, 1993)

Outcome Of AMI 3-month mortality p<0.05 (Fava S et al, Diabetes Care 16:1615-8, 1993)

p< p< 0.05

Loss of ‘R’ to ‘R’ variability and Mortality p<0.05 (Fava S et al, Diabetes Care 16:1615-8, 1993)

Loss of ‘R’ to ‘R’ variability and LVF p<0.02 (Fava S et al, Diabetes Care 16:1615-8, 1993)

Thrombolysis p<0.05

Mortality after AMI: Recent Data Murcia AM et al: Impact of Diabetes on Mortality in Patients With Myocardial Infarction and Left Ventricular Dysfunction. Arch Intern Med. 2004;164:

Outcome Of Unstable Angina p=0.014 p=0.029 Fava S et al, Diabet Med, 14: , 1997

Drug Rx After Unstable Angina NitratesCCBAspirin β- Blockers Fava S et al, Diabet Med, 14: , 1997 NS p=0.008

Invasive Procedures at 1 year After Unstable Angina p= 0.04 NS p= Fava S et al, Diabet Med, 14: , 1997

Impact of Albuminuria Gerstein HC et al: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA Jul 25;286(4):421-6

Log-rank test p = Kaplan-Meier survival plot Parents of patients with T1 DM with nephropathy Parents of with T1 DM without nephropathy Tarnow L et al, Diabetes Care 23 :30–33, 2000

SURVIVAL IN DIABETIC NEPHROPATHY AND ACE GENOTYPE Fava S et al, Diabetes Care 24: , 2001 p<0.05

Circadian Variation in Onset of AMI χ 2 = 13.9, P < χ 2 = 1.66, NS Non-diabetic subjectsDiabetic subjects Fava S et al, Heart 1995;74;

Circadian Variation in Onset of AMI Rana JS et al: Circadian Variation in the Onset of Myocardial Infarction. Effect of Duration of Diabetes. Diabetes 52: , 2003

Circadian Variation in Onset of Acute Pulmonary Oedema χ 2 = 9.38, P < χ 2 = 0.34, NS Fava S & Azzopardi J. Am J Cardiol 1997 APE AMI

Plasma Glucose in Diabetic Patients with AMI Fava S et al: The prognostic significance of Blood Glucose in Diabetic Patients with Acute Myocardial Infarction. Diabetic Med, 1996:13: r = 0.92, p< 0.04

Malmberg, K. BMJ 1997;314:1512 Actuarial mortality curves during long term follow up in patients receiving insulin-glucose infusion and in control group among total DIGAMI cohort. Absolute risk reduction was 11% DIGAMI RR 0.72 (0.55 to 0.92), p=0.011

Conclusions (1) Diabetes is associated with increased mortality after AMI and unstable angina Loss of ‘R’ to ‘R’ variability and  PG on admission are associated with increased mortality in diabetic patients with AMI Outcome after AMI may be improved with tight glycaemic control in the acute stage Mater Dei Hospital, Malta

Conclusions (2) Diabetic patients with ACS should be managed aggressively to lower this risk Diabetic patients with renal disease are at a particularly  risk; this is probably partly genetically mediated There is loss of circadian rhythm in the onset of AMI & APE in diabetic patients~ ? implications for chronopharmacology Mater Dei Hospital, Malta